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Abstract
Background: This study evaluates the associations between high-sensitivity troponin I and T (hs-TnI/hs-TnT) and the
stages of heart failure with preserved ejection fraction (HFpEF)/diastolic dysfunction.
Methods: Blood samples for biomarker measurements (hs-TnI/hs-TnT/NT-proBNP) were collected within 24 h of
routine echocardiographic examination. Patients with left ventricular ejection fraction <50%, right ventricular dysfunc-
tion and moderate-to-severe valvular heart disease were excluded. Graduation of diastolic dysfunction was determined
according to current guidelines.
Results: A total of 70 patients were included. Hs-TnT concentrations increased significantly according to the progres-
sion of diastolic dysfunction (P¼ 0.024). Hs-TnT was able to discriminate patients with diastolic dysfunction grade III
(AUC¼ 0.737; P¼ 0.013), while NT-proBNP revealed a greater AUC (AUC 0.798; P¼ 0.002). Concentrations of hs-TnI
increased only numerically according to the increasing stages of diastolic dysfunction (P¼ 0.353). In multivariable logistic
regression models, hs-TnT concentrations> 28 ng/L were associated with diastolic dysfunction grade III (OR¼ 4.7,
P¼ 0.024), even after adjusting for NT-proBNP.
Conclusion: Increasing concentrations of hs-TnT may reflect the stages of diastolic dysfunction being assessed by
echocardiography, whereas hs-TnI does not show any association with diastolic dysfunction.
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Introduction
Heart failure with preserved ejection fraction (HFpEF)
accounts for 50% of all heart failure syndromes, and its
rising prevalence, often credited to demographic varia-
tions and a widening cardiovascular risk factor profile,
represents a growing epidemiological problem.1–4
The pathophysiology of HFpEF and the cardiac
phenotypes in these patients are typically heteroge-
neous.1,5 Myocardial relaxation, myocardial compli-
ance and left ventricular (LV) pressure are the triad
of factors serving the basis of our understanding of
diastolic function. Causal connections like age, ischae-
mia and hypertrophy have been associated with
impaired myocardial relaxation, while scarring and
fibrosis reduce myocardial compliance necessitating
higher filling pressures.6 A recent study has suggested
that chronic inflammation and coronary microcircula-
tory disturbances may also influence the pathophysiol-
ogy of HFpEF.1 The integration of these influences and
contrasting views facilitates the opening of various
target points for novel diagnostic biomarkers and phar-
macological therapies.
Echocardiography is the most common imaging
technique in clinical cardiology practice. As a non-
invasive method, it allows a real-time overview of the
cardiac function.7 The use of echocardiographic
parameters to assess impaired myocardial diastolic
function is influenced by contextual factors such as
emphysema and adiposity. These factors serve as an
impediment against a fully objective and accurate
assessment of the cardiac status. The use of biomarkers
to quantify cardiac dysfunction in HFpEF is naturally
free of such disadvantages; however, early studies
researching these have yielded disappointing results.
This has been partly attributed to their poor
reliability.8
B-type natriuretic peptide (BNP) and its amino-
terminal precursor (NT-proBNP) shows significant
association with echocardiographic parameters used
to diagnose diastolic dysfunction. Although there has
been no conclusive evidence demonstrating a specific
association of serum BNP and NT-proBNP concentra-
tions to HFpEF patients, it has been implied that a
non-linear correlation between varying serum concen-
trations of NT-proBNP and increased risks in cardio-
vascular mortality as well as re-hospitalization exists.9
Increased concentrations of cardiac troponin (cTn)
in patients with HFpEF vary between 22% to 44%
(conventional assay) and 55% to 72% (hs-assay).10
Additionally, serum concentrations of cTn correlate
significantly with LV mass and size, left atrial (LA)
diameter and the severity of diastolic dysfunction as
determined by echocardiography. A comparison of
cTn concentration in patients with HFrEF and
HFpEF showed lower values for patients diagnosed
with the latter variant.10 Nevertheless, it appears that
high-sensitivity troponin T (hsTnT) has significant
prognostic value for overall survival and re-
hospitalization among HFpEF patients.11 A recent
study from Japan reported that an increased high-
sensitivity troponin I (hsTnI) concentration in combi-
nation with elevated serum concentrations of
NT-proBNP correlates better to the risk of developing
heart failure in patients diagnosed with hypertension
and preserved ejection fraction.12
These data serve as the basis of our study, which sets
out to investigate the hypothesis that quantitative con-
centrations of hsTnI and/or hsTnT could reflect the
severity of the diastolic dysfunction and correspond
to echocardiographic parameters associated
with HFpEF.
Methods
Study population
The ‘Cardiovascular Imaging and Biomarker Analyses’
(CIBER) study (clinicaltrials.gov identifier: NCT
03074253) represents a clinically prospective, con-
trolled and monocentric study conducted at the
University Medical Center Mannheim, Germany.
The research adhered to the principals outlined in the
Declaration of Helsinki and was approved by a region-
al ethics committee. Written informed consent was
obtained from all patients.
For the present study, patients presenting to our
echocardiography laboratory with compensated
HFpEF as being assessed by routine echocardiographic
imaging were included between 2014 and 2016. Patients
under the age of 18 years, left ventricular ejection frac-
tion <50%, reduced right ventricular function (RVF)
corresponding to a tricuspid annular posterior systolic
excursion (TAPSE) <17 mm and moderate to severe
valvular heart disease were excluded from this study.
All relevant clinical data including the medical his-
tory, results of echocardiographic assessment and the
laboratory blood values at baseline were collected from
the hospital documentation system and summarized in
a database for further reference. Follow-ups were
scheduled for all patients after 6 and 12 months
by telephone or personal visits in case of
re-hospitalization.
Transthoracic echocardiography. Transthoracic echocardi-
ography was carried out by independent echocardio-
graphic specialists/physicians using standard
techniques according to the guidelines established by
ASE/EACVI to acquire reproducible images.13,14 The
results were checked and revised by an independent
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study physician being well experienced in the assess-
ment of HFpEF and being unaware of the patients
clinical and biomarker data.
Assessment of the systolic function with the ejection
fraction (EF using Simpsons biplan method), end-
systolic and -diastolic volumes and diameters, right
ventricular (RV) function with TAPSE and valvular
heart diseases were included in the investigation. The
classification of the diastolic dysfunction was deter-
mined by the mitral inflow velocities examination (E
and A) and the mitral annular velocities examination
(E’). In patients with atrial fibrillation, the LV end-
diastolic pressure (LVEDP) was measured to evaluate
the diastolic function. Patients were divided into the
four groups: Patients with good diastolic function, dia-
stolic dysfunction grade 1, grade 2 or grade 3. Details
for HFpEF classification based on echocardiography
are outlined in supplemental Table 1 for concise pre-
sentation purpose.
Laboratory analysis. All expressed biomarkers were mea-
sured in the serum of patients’ blood. Within 24 h
before or after the echocardiographic imaging, periph-
eral venous blood samples were taken from each
patient and collected in serum monovettesVR tubes and
centrifuged at 2500 g for 10 min at 20C. The aliquoted
samples were cooled down with liquid nitrogen before
being stored at –80C until analysis. The whole proc-
essing took part within 2 h after blood extraction. After
thawing, the samples were mixed gently by inverting
and centrifuged at 2500 g for 10 min at 20C for
Troponin T and N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) and creatinine analysis.
For TnI measurement, the samples were gently
mixed by inverting after thawing and centrifuged for
30 min at 3000 g at 4C. Troponin I was measured with
the STAT High Sensitive Troponin-I assay on an
Architect i1000 analyzer (Abbott, Wiesbaden,
Germany) with a limit of blank (LoB) of
0.7–1.3 ng/L and a limit of detection (LoD) of
1.1–1.9 ng/L. The 10% imprecision was at 4.7 ng/L.
The 99th percentile was at 26.2 ng/L.15 The reportable
range for our study was 0–50,000 ng/L. Troponin T
was measured with the Troponin T hs STAT assay
on a cobas e 602 analyzer (Roche Diagnostics,
Mannheim, Germany). The LoB for this assay was 3
ng/L and the LoD 5 ng/L. The 10% imprecision was 13
ng/L. The 99th percentile was at 14 ng/L.16 The report-
able range for our study was 3–10,000 ng/L. NT-
proBNP was measured with the proBNP II STAT
assay on a cobas e 602 analyzer (Roche Diagnostics,
Mannheim, Germany). The LoD was at 0.6 pmol/L.
The reportable range for our study was 0.6–4130
pmol/L.17 Serum creatinine was measured with the
Creatinine Jaffe Generation 2 assay on a cobas c 702
system. The LoD was 15 lmol/L. The reportable range
for our study was 41–2226 lmol/L.18 C-reactive protein
(CRP), gamma-glutamyl-transferase (GGT) and lactic
dehydrogenase (LDH) were determined under ISO-
15189 accreditation conditions. Samples in Li-Hep
MonovettesVR (Sarstedt, Nu¨mbrecht, Germany) were cen-
trifuged at 2500 g for 10 min at 20C and subsequently
analysed on Vista Dimension 1500 platform (Siemens,
Eschborn, Germany). CRP was determined by
microparticle-enhanced nephelometric immunoassay
(Siemens, Eschborn, Germany) with analytical measuring
range (AMR) from 0.29 to 190 mg/L. GGT and LDH
assays are both based on bichromatic kinetics (Siemens,
Eschborn, Germany) and show an AMR from 3 to 800
U/L for GGT, and 6 to 1000 U/L for LDH.
Statistical analysis. Statistical analysis was conducted for
all patients’ data as well as the four predefined sub-
groups according to the severity of HFpEF. The
Student’s t-test was used with variables following
normal distribution, otherwise the Kruskal-Wallis test
(non-parametric test) was appointed as the method of
choice. Discrepancies from Gaussian distribution were
furthermore screened by the Kolmogorov-Smirnov test
to accommodate and adjust for the relatively small
sample size. Depending on the distribution, all data
are presented as mean with confidence interval (CI)
or median with interquartile ranges (IQR; 25th to
75th percentiles).
Correlation of hsTnT and hsTnI serum concentrations
with non-parametric data, such as echocardiographic indi-
ces and medical parameters, is determent by the
Spearman’s rank correlation coefficient. Cut-offs for the
biomarkers was set at the group-specific medians of each
biomarker. Multivariable linear or logistic regression anal-
ysis with backward elimination was performed to identify
any potential source of irritation. Subsequently, depend-
ing on the significance of those irritations’ adjustments of
several clinical parameters or biomarkers were carried out.
The Hanley and McNeil method were implemented to
identify if hsTnT or hs TnI was more accurate than
NT-proBNP in the identification of HFpEF.19
Tests were carried out using SPSS software (SPSS
Software GmbH, IBM, Armonk, NY) and statistical
significance was attained whenever the observed
P-value of a test statistic was less than 0.05.
Results
Study population
A total of 70 HFpEF patients aged between 22 years
and 97 years were included in this study. The baseline
clinical characteristics are shown in Table 1. The mean
age was 65 years and baseline demographics
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represented a balanced gender distribution, with 49%
of the study population being women. The median cre-
atinine value was estimated to be 82.21 lmol/L (range
67.76–101.2 lmol/L) in the total cohort. Interestingly,
arterial hypertension was noticed in almost 80% of the
study patients (n¼ 56), effectively proving arterial
hypertension as a predominant risk factor for
HFpEF patients. Cardiac co-morbidities such as
atrial fibrillation was diagnosed in 38% of the patients,
whereas 50% suffered from pre-existing coronary
artery disease, although only 7% of these presented
themselves with a prior history of myocardi-
al infarction.
Echocardiographic assessment
Based on the significant correlation between HFpEF
and E/A (P¼ 0.0001), E’ lat (P¼ 0.009) and E/E’
(P¼ 0.0001) parameters, the group population was seg-
regated accordingly to allow differential analysis. Study
patients were diagnosed with either a good diastolic
function (20%; n¼ 14) or a diastolic dysfunction
grade I (21%; n¼ 15), grade II (43%; n¼ 30) or
grade III (16%; n¼ 11).
Detailed results of the distribution of echocardio-
graphic indices among the HFpEF subgroups are
described in Tables 2 to 4. Consistent with the trial
inclusion criteria, neither the ejection fraction
(P¼ 0.109) nor TAPSE (P¼ 0.41) differed significantly
among the HFpEF subgroups. Echocardiographic
parameters attributed to have statistical significance
include the LV posterior wall thickness (LVPW;
P¼ 0.045), LA dimensions (P¼ 0.044) and LA
volume (P¼ 0.002).
Characteristics of hsTnT and hsTnI in the present
HFpEF cohort
HsTnT reflected the progression of HFpEF and
increased concentrations corresponded to the develop-
ment of diastolic dysfunction (P¼ 0.024).
Concentrations of hsTnI increased only numerically
according to increasing stages of HFpEF (P¼ 0.353).
The distribution of hsTnT, hsTnI and NT-proBNP
concentrations is graphically reproduced in Figure 1.
Correlation between hsTnT and both baseline
characteristics and echocardiographic indices
Univariable correlations between hsTnT and both
baseline characteristics and echocardiographic indices
are given in Table 5. HsTnT demonstrated a strong
relation to serum creatinine (P¼ 0.0001) and age
(P¼ 0.0001). In this scenario, a significant correlation
with the reference biomarker for chronic heart failure,
NT-proBNP was also evident in each subgroup of
HFpEF (P¼ 0.0001; range 0.011–0.0001). The relation-
ship between parameters indicating HFpEF and hsTnT
can only be described as a tendency (E/A, P¼ 0.334
and E/E’, P¼ 0.078). Serum concentrations of hsTnT
in all patients corresponded with echocardiographic
indices describing the LA chamber (LA-diameter,
P¼ 0.003 and LA-area, P¼ 0.0001). Furthermore, an
association to wall thickness as well as the LV endsys-
tolic diameter (LVESD) could be ascertained (LVESD,
P¼ 0.004; LVPW, P¼ 0.002; IVSD, P¼ 0.0001).
Interestingly, these correlations could only be
Table 1. Baseline characteristics of study patients.
Characteristics HFpEF (n¼ 70)
Age, mean (range; 95% CI) 65 (22–97; 84)
Gender, n (%)
Male 36 (51)
Female 34 (49)
Cardiovascular risk factors, n (%)
Arterial hypertension 56 (80)
Hypercholesterinaemia 26 (37)
Cardiac family history 11 (16)
Smoking status 23 (33)
Diabetes mellitus 17 (24)
Adipositas 16 (23)
Laboratory parameters, median (IQR)
Creatinine (lmol/L) 82.21 (67.76–101.2)
GFR 70.47 (51.37–88.84)
Medical history, n (%)
Chronic heart failure 64 (91)
NYHA I 36 (51)
NYHA II 10 (14)
NYHA III 17 (24)
NYHA IV 1 (1)
Atrial fibrillation 27 (39)
Paroxysmal 15 (21)
Persistent 9 (13)
Permanent 3 (4)
Coronary artery disease 35 (50)
One vessel disease 4 (6)
Two vessel disease 12 (17)
Three vessel disease 19 (27)
Myocardial infarction 5 (7)
Chronic kidney disease 12 (17)
COPD 8 (11)
Asthma 2 (3)
Cancer 18 (26)
CI: confidence interval; IQR: interquartile range; COPD: chronic
obstructive pulmonary disease; GFR: glomerular filtration rate; HFpEF:
heart failure with preserved ejection fraction.
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individually determined in grade II diastolic dysfunc-
tion (LA-diameter, P¼ 0.047; LA-area, P¼ 0.006;
LVESD, P¼ 0.012; LVPW, P¼ 0.004; IVSD,
P¼ 0.0001). In all patients, hsTnT corresponded to
laboratory values of cell downfall, signs of inflamma-
tion as well as GGT (LDH, P¼ 0.001; CRP, P¼ 0.039;
GGT, P¼ 0.017).
Correlation between hsTnI and both baseline
characteristics and echocardiographic indices
Demonstrations of hsTnI association to baseline charac-
teristics as well as echocardiographic indices through a
univariate linear regression analysis are outlined in Table
6. A strong correlation with serum creatinine
(P¼ 0.0001) is shown through all groups of HFpEF. A
relationship with the reference biomarker NT-proBNP,
describing chronic heart failure, could be reproduced in
all patients (P¼ 0.001). Meanwhile, the concentration of
correlation between the biomarker and the different
subgroups, defined by varying severities of diastolic dys-
function, was insignificant. Surprisingly, concentrations
of hsTnI did not correspond with any echocardiographic
indices suggesting HFpEF (E/A, P¼ 0.386 and E/E’,
P¼ 0.317). Serum concentrations of hsTnI in all patients
corresponded significantly to LVPW (P¼ 0.013) and
IVSD (P¼ 0.001), whereas this was statistically insignif-
icant across the various HFpEF subgroups.
Additionally, there existed a significant positive correla-
tion between the right ventricular volume and patients
with HFpEF grade I (P¼ 0.009). This relationship was
not expressed in other subgroups with advanced diastolic
dysfunction.
hsTnT discriminates patients with diastolic
dysfunction grade III
Receiver-operating characteristic (ROC) analysis
revealed that hsTnT were able to identify patients
with HFpEF grade III (AUC 0.737; P¼ 0.013)
Table 2. Distribution of echocardiographic indices according to HFpEF subgroups.
Good diastolic function
(n¼ 14)
Diastolic dysfunction I
(n¼ 15)
Diastolic dysfunction II
(n¼ 30)
Diastolic dysfunction III
(n¼ 11) P
LVEF (%) 61.00 (56.00–65.00) 58.00 (57.00–62.00) 62.00 (56.00–67.00) 56.00 (54.00–58.00) 0.109
LVEDD (mm) 45.00 (42.00–46.00) 44.00 (43.00–48.00) 46.00 (40.00–50.00) 50.00 (45.00–58.00) 0.112
LVESD (mm) 30.00 (26.00–32.00) 29.00 (27.00–35.00) 28.00 (27.00–32.00) 31.00 (28.00–37.00) 0.39
LVPW (mm) 10.00 (8.00–11.00) 10.00 (9.00–12.00) 11.00 (10.00–12.00) 12.00 (11.00–14.00) 0.045
LVIS (mm) 11.00 (9.00–12.00) 11.00 (10.00–12.00) 12.00 (10.00–13.00) 13.00 (12.00–13.00) 0.065
RA (mm) 35.00 (31.00–40.00) 37.00 (35.00–38.00) 35.00 (32.00–40.00) 36.00 (34.00–41.00) 0.911
RA (cm3) 13.00 (11.00–16.00) 15.00 (13.00–16.00) 14.00 (12.00–15.00) 17.00 (14.00–18.00) 0.172
LA (mm) 35.00 (34.00–38.00) 40.00 (36.00–45.00) 39.00 (35.00–41.00) 43.00 (40.00–47.00) 0.044
LA (cm3) 15.00 (11.00–17.00) 17.00 (16.00–18.00) 17.00 (15.00–20.00) 24.00 (20.00–27.00) 0.002
RV-area (cm3) 18.00 (14.00–21.00) 18.00 (17.00–20.00) 18.00 (16.00–21.00) 19.00 (15.00–22.00) 0.926
RV-volume (ml) 34.00 (25.00–43.00 ) 40.00 (31.00–44.00) 37.00 (29.00–52.00) 38.00 (26.00–53.00) 0.634
LV-area (cm3) 33.00 ( 28.00–35.00 ) 39.00 (31.00–44.00) 34.00 (31.00–39.00) 37.00 (33.00–42.00) 0.099
LV-volume (ml) 114.00 (89.00–130.00 ) 149.00 (99.00–170.00) 111.00 (90.00–137.00) 128.00 (92.00–176.00) 0.218
Aorta (mm) 28.00 (26.00–31.00 ) 28.00 (26.00–38.00) 30.00 (27.00–33.00) 31.00 (29.00–32.00) 0.466
AortaPmean (mmHg) 8.00 (8.00–8.00) 9.00 (9.00–9.00) 9.80 (5.50–14.00) 9.00 (7.00–11.00) 0.986
AortaPmax (mmHg) 6.00 (5.00–7.00) 9.00 (6.00–10.00) 8.00 (6.00–10.00) 7.00 (6.00–13.00) 0.236
TAPSE (mm) 22.00 (21.00–25.00) 21.00 (19.00–23.00) 23.00 (21.00–26.00) 20.00 (19.00–18.00) 0.41
E/A (cm/s) 1.20 (1.10–1.50) 0.80 (0.60–0.90) 0.80 (0.70–1.10) 0.90 (0.80–1.30) 0.0001
E’med (m/s) 0.11 (0.09–0.13) 0.07 (0.05–0.08) 0.06 (0.05–0.08) 0.04 (0.04–0.06) 0.002
E’lat (m/s) 0.10 (0.08–0.13) 0.09 (0.07–0.11) 0.08 (0.06–0.09) 0.05 (0.05–0.06) 0.009
E/E’ 6.00 (4.00–7.00) 7.00 (6.00–8.00) 11.00 (10.00–12.00) 19.00 (16.00–26.00) 0.0001
DT (ms) 214.00 (164.00–237.00) 243.00 (187.00–299.00) 240.00 (205.00–296.00) 236.00 (192.00–373.00) 0.119
IVRT (ms) – – 514.00 (514.00–514.00) – –
LVEF: left ventricular ejection fraction; LVEDV: LV enddiastolic volume; LVESV: LV endsystolic volume; LVPW: LV posterior wall; IVSD: interventricular
septal diameter; RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle; TAPSE: tricuspid annular plane systolic excursion; E/A: ratio of
the early (E) to late (A) ventricular filling velocities; E/E’: ratio of mitral inflow (E) velocity to tissue Doppler (E’); DT: deceleration time; IVRT:
isovolumic relaxation time.
Note: Data presented as median with interquartile ranges (IQR). Bold values indicate statistically significant P values (P< 0.05).
Hoffmann et al. 435
(Figure 2(a)). NT-proBNP as the reference biomarker
also detected such characteristics, admittedly with a
greater AUC (AUC 0.798; P¼ 0.002). Additionally,
the combination of hsTnT and NT-proBNP showed
no improvement in the diagnostic accuracy of diastolic
dysfunction grade III (AUC 0.767; P¼ 0.005).
The AUC for hsTnI discriminating diastolic dysfunc-
tion grade III was 0.667 (P¼ 0.08) (Figure 2(b)).
Multivariate logistic regression models for evaluating
diastolic dysfunction grade III with hsTnT
Multivariate logistic regression models for log-
transformed hsTnT were adjusted according to its
strong correlation with baseline characteristics such
as gender, age, creatinine, NT-proBNP concentrations
and echocardiographic indices such as the left atrial
diameter (Table 5). After stepwise backward analysis,
results indicated that the probability of diagnosis with
diastolic dysfunction grade III in patients with hsTnT
concentrations >2.8 ng/L increased almost fivefold
(adjusted odds ratio [OR]¼ 4.7, 95% CI: 1.224–
18.049, P¼ 0.024). Patients with serum concentrations
of NT-proBNP> 74.57 pmol/L were not significantly
associated with HFpEF grade III in this model (adjust-
ed OR¼ 1.442; 95% CI 0.237–8.763, P¼ 0.691).
Multivariate logistic regression models for evaluating
diastolic dysfunction grade III with hsTnI
Results from the correlation analysis dictated that the
log-transformed hsTnI multivariate logistic regression
Table 3. Univariable correlations between hsTNT and baseline characteristics, biomarkers and echocardiographic indices according
to HFpEF subgroups.
All patients
(n¼ 70)
Good diastolic
function (n¼ 14)
Diastolic
dysfunction I
(n¼ 15)
Diastolic
Dysfunction II
(n¼ 30)
Diastolic
Dysfunction III
(n¼ 11)
R P r P r P r P r P
Age 0.413 0.0001 0.302 0.294 0.160 0.569 0.390 0.033 0.209 0.537
Creatinine 0.534 0.0001 0.252 0.385 0.427 0.128 0.558 0.002 0.251 0.457
NT-proBNP 0.645 0.0001 0.452 0.104 0.815 0.0001 0.619 0.0001 0.727 0.011
LVEF –0.18 0.137 0.199 0.494 –0.383 0.159 –0.129 0.498 –0.414 0.206
LVEDD 0.306 0.100 0.009 0.976 0.297 0.283 0.344 0.063 0.233 0.491
LVESD 0.343 0.004 0.236 0.417 0.245 0.399 0.451 0.012 0.087 0.800
LVPW 0.358 0.002 0.403 0.153 –0.016 0.954 0.505 0.004 0.07 0.838
IVSD 0.455 0.0001 0.418 0.137 0.050 0.860 0.605 0.0001 0.207 0.542
RA-diameter 0.195 0.109 0.068 0.818 0.292 0.290 0.178 0.356 0.398 0.225
LA-diameter 0.348 0.003 0.008 0.979 0.275 0.321 0.366 0.047 0.307 0.359
LA-area 0.436 0.0001 0.223 0.444 0.149 0.626 0.522 0.006 0.455 0.257
RV-area 0.114 0.349 –0.019 0.948 –0.205 0.465 0.313 0.093 0.223 0.509
RV-volume 0.177 0.142 0.251 0.386 –0.313 0.256 0.346 0.061 0.255 0.450
LV-area 0.107 0.418 0.068 0.825 –0.140 0.649 0.127 0.554 –0.233 0.546
LV-volume –0.012 0.921 0.135 0.645 –0.179 0.523 –0.09 0.636 –0.20 0.555
TAPSE –0.164 0.176 –0.149 0.610 –0.183 0.513 –0.126 0.506 –0.352 0.289
Aorta 0.154 0.210 0.520 0.083 –0.208 0.458 0.081 0.672 –0.179 0.598
E/A –0.12 0.334 –0.09 0.769 –0.210 0.452 –0.205 0.287 0.188 0.603
E/E’ 0.233 0.078 0.196 0.673 0.186 0.584 –0.066 0.730 0.109 0.763
DT –0.007 0.954 0.059 0.843 –0.357 0.210 0.139 0.471 –0.15 0.700
LDH 0.591 0.0001 0.714 0.111 0.368 0.330 0.436 0.055 0.90 0.037
y-GT 0.371 0.017 0.928 0.008 –0.085 0.828 0.377 0.092 0.30 0.624
D-Dimer 0.314 0.154 – – 0.450 0.310 –0.046 0.893 1.00 –
CRP 0.255 0.039 0.099 0.736 0.557 0.038 0.100 0.621 0.554 0.077
Cholesterol –0.268 0.094 0.829 0.042 –0.787 0.012 –0.228 0.321 –0.40 0.600
LVEF, left ventricular ejection fraction; LVEDD: LV enddiastolic diameter; LVESD: LV endsystolic diameter; LVPW: LV posterior wall thickness; IVSD:
Interventricular septal diameter; RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle; TAPSE: tricuspid annular plane systolic
excursion; E/A: ratio of the early (E) to late (A) ventricular filling velocities; E/E’/: ratio of mitral inflow (E) velocity to tissue Doppler (E’).
Note: Bold values indicate statistically significant P values (P< 0.05)
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model be adjusted to gender, age, creatinine, NT-
proBNP and LA-diameter (Table 5). Noteworthy,
patients with hsTnI> 24.7 ng/L were not significantly
associated with diastolic dysfunction grade III (adjust-
ed OR¼ 1.949, 95% CI: 0.477–7.970, P¼ 0.353),
whereas NT-proBNP as the reference biomarker
revealed a fourfold higher risk for HFpEF grade III
with NT-proBNP-concentrations> 74.57 pmol/L
(adjusted OR¼ 4.083, 95% CI: 1.040–
16.035, P¼ 0.044).
Discussion
The present study evaluates the association of
high-sensitivity troponin I and T in patients with
compensated HFpEF being assessed by transthoracic
echocardiography. It was demonstrated that hsTnT
revealed to be a reliable biomarker reflecting all
stages of diastolic dysfunction, especially in discrimi-
nating the severe stage III. Noteworthy, hsTnI did
not reveal consistent significant associations with the
stages of diastolic dysfunction, whereas the reference
biomarker NT-proBNP reflected diastolic dysfunction
as comparable to hsTnT. Patients in this study cohort
were all in compensated stages of diastolic dysfunction,
and the results were proven both in univariate as well
as multivariable statistical models.
While many studies have analysed the role of bio-
markers in the diagnosis of heart failure, most research
has focused on its role in HFrEF. The potential use of
Table 4. Univariable correlations between hsTNI and baseline characteristics, biomarkers and echocardiographic indices according
to HFpEF subgroups.
All patients
(n¼ 70)
Good Diastolic
function
(n¼ 14)
Diastolic
dysfunction I
(n¼ 15)
Diastolic
Dysfunction II
(n¼ 30)
Diastolic
Dysfunction III
(n¼ 11)
r P r P r P r P r P
Age 0.218 0.069 0.163 0.578 –0.061 0.829 0.152 0.421 0.345 0.298
Creatinine 0.415 0.0001 0.270 0.350 0.393 0.165 0.415 0.025 –0.141 0.679
NT-proBNP 0.373 0.001 0.420 0.135 0.440 0.101 0.273 0.145 0.727 0.011
LVEF –0.124 0.307 0.119 0.684 –0.463 0.082 –0.023 0.905 0.014 0.968
LVEDD 0.107 0.377 0.042 0.887 0.130 0.644 –0.019 0.919 –0.219 0.517
LVESD 0.133 0.278 0.150 0.608 –0.037 0.901 0.131 0.489 0.159 0.640
LVPW 0.294 0.013 0.038 0.898 0.094 0.739 0.358 0.052 0.243 0.472
IVSD 0.412 0.0001 0.198 0.497 0.415 0.124 0.306 0.100 0.348 0.295
RA-diameter 0.149 0.220 0.234 0.420 0.123 0.662 0.156 0.419 0.137 0.687
LA-diameter 0.156 0.198 –0.115 0.695 0.139 0.621 0.102 0.590 0.215 0.525
LA-area 0.061 0.640 –0.033 0.911 0.237 0.435 –0.232 0.254 0.192 0.649
RV-area –0.027 0.825 0.357 0.210 –0.461 0.084 0.000 0.998 –0.150 0.659
RV-volume –0.125 0.302 –0.035 0.905 –0.647 0.009 –0.021 0.911 –0.155 0.650
LV-area 0.007 0.955 0.356 0.232 0.079 0.798 –0.218 0.306 –0.267 0.488
LV-volume –0.060 0.621 0.229 0.431 –0.090 0.749 –0.147 0.438 –0.218 0.519
TAPSE 0.009 0.942 0.060 0.838 –0.141 0.617 0.277 0.138 –0.583 0.060
Aorta 0.168 0.171 0.236 0.460 0.169 0.547 0.124 0.514 0.046 0.893
E/A –0.108 0.386 0.398 0.178 –0.045 0.874 –0.213 0.268 –0.212 0.556
E/E’ 0.134 0.317 0.543 0.208 –0.053 0.876 0.089 0.639 –0.207 0.567
DT 0.050 0.692 0.033 0.911 –0.238 0.413 0.086 0.655 0.133 0.732
LDH 0.296 0.063 0.714 0.111 0.033 0.932 0.179 0.450 0.800 0.104
y-GT 0.089 0.580 0.371 0.468 –0.237 0.539 0.085 0.714 –0.100 0.873
D-Dimer –0.003 0.991 – – –0.027 0.954 0.000 1.000 1.000 –
CRP 0.122 0.328 –0.160 0.586 0.222 0.445 0.191 0.340 0.130 0.703
Cholesterol 0.094 0.565 0.829 0.042 –0.400 0.286 0.016 0.944 0.000 1.000
LVEF: left ventricular ejection fraction; LVEDD: LV enddiastolic diameter; LVESD: LV endsystolic diameter; LVPW: LV posterior wall thickness; IVSD,
Interventricular septal diameter; RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle; TAPSE, tricuspid annular plane systolic
excursion; E/A: ratio of the early (E) to late (A) ventricular filling velocities ; E/E’: ratio of mitral inflow (E) velocity to tissue Doppler (E’).
Note: Bold values indicate statistically significant P values (P< 0.05).
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biomarkers other than BNP and NT-proBNP, which
could define the prognosis in HFpEF has been poorly
researched. Perhaps, the complex underlying
pathophysiology contributing to the development of
HFpEF has compounded to this problem. Early
research work attempting to explain the HFpEF syn-
drome suggested a systemic component, rather than the
influence of local myocardial pathologies as in the case
of HFrEF.1 An examination of specific target points
commonly associates the origins of HFpEF with
inflammation, fibrosis and myocardial stress.20
The results of the present study have been highlight-
ed. Firstly, hsTnT was able to discriminate patients
with severe diastolic dysfunction. This relevance
could be increased by combining the measurements
with NT-proBNP, while the pure NT-proBNP meas-
urements remained the most significant. To explore the
implications of this positive relation between diastolic
dysfunction and hsTnT, the different attributes of the
protein must be considered. TnT as a subunit of the
troponin complex is an integral protein in the
Figure 1. Distribution of hs-TnT (panel A), hs-TnI (panel B) and
NT-proBNP (panel C) serum concentrations according to sub-
groups of diastolic dysfunction. Data are presented as medians
with 25th and 75th percentiles (boxes) and 5th and 95th per-
centiles (whiskers).
Table 5. Multivariable logistic regression model for evaluating
the ability of hsTnT to identify patients with diastolic dysfunc-
tion III.
Adjusted
odds ratio 95% CI Adjusted P
hsTnT (28 ng/L) 4.700 1.224–18.049 0.024
NT-proBNP
(74.57 pmol/L)
1.442 0.237–8.763 0.691
Gendera 1.049 0.263–4.194 0.946
Creatinine 1.075 0.348–3.322 0.900
LA (>45 mm) 2.586 0.643–10.400 0.181
Note: Bold values indicate statistically significant P values (P< 0.05).
CI: confidence interval; LA: left atrium; hsTnT: high sensitivity troponin T.
aAn adjusted odds ratio of >1 indicates an association of male gender
with diastolic dysfunction III.
Table 6. Multivariable logistic regression model for evaluating
the ability of hsTnI to identify patients with diastolic dysfunc-
tion III.
Adjusted
odds ratio 95% CI
Adjusted
P value
hsTnI (24.7 ng/L) 1.949 0.477–7.970 0.353
NT-proBNP
(74.57 pmol/L)
4.083 1.040–16.035 0.044
Gendera 1.020 0.255–4.079 0.978
Creatinine 1.343 0.427–4.222 0.614
LA (>45 mm) 2.233 0.526–9.489 0.276
Note: Bold values indicate statistically significant P values (P< 0.05).
CI: confidence interval; NT-proBNP: B-type natriuretic peptide and its
amino-terminal precursor.
aAn adjusted odds ratio of >1 indicates an association of male gender
with diastolic dysfunction III.
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contractile apparatus in striated muscle cells. After
forming a union with calcium (Ca), the complex
binds to tropomyosin and thereby releases it from the
myosin head, resulting in muscle contraction.21 Injuries
and loss of permeability in the cell membrane cause
increased serum concentrations of TnT.22 Many studies
have shown that TnT is an important marker in diag-
nosing an acute coronary syndrome (ACS) and chronic
systolic heart failure.10,11,23,24 However, the identified
significant correlation found in this study has led to
examine its role in and relation to the origin and devel-
opment of diastolic dysfunction.
One of the most common features emphasized in
HFpEF patients is arterial hypertension. The increased
arterial blood pressure could facilitate the release of
TnT, an indicator of cell decay, in the event of cardio-
myocyte damage in this syndrome.25 The causal chain
is set in motion by the resulting LV hypertrophy lead-
ing to diastolic wall stress and thereby a compromised
coronary microvascular function. This in turn causes
vascular reorganization and a decreased tolerance for
ischaemia. The consequent inadequate supply of
oxygen effects cardiomyocyte damage and scarring,
which again increases diastolic wall stress creating a
vicious cycle.25
This pathological chain of events finds support in
our study, suggesting significant correlation between
echocardiographic indicators of LV hypertrophy and
TnT measurements in patients with severe diastolic
dysfunction. While studies highlighting the correlation
of hsTnT to HFrEF and HFpEF found a stronger
association of hsTnT to patients with systolic heart
failure,11,26 this study provides evidence of a significant
relationship between hsTnT and diastolic dysfunction
grade III. It suggests some myocardial damage in the
severe stages of diastolic dysfunction, which can be
explained through the vicious cycle outlined above.
However, due to the lower level of correlation, this
does not affect the previous assumptions that HFpEF
constitutes a systemic or metabolic illness rather than a
myocardial-specific condition such as HFrEF.
While previous studies revealed a significant role of
TnI in cardiac relaxation, this study does not find a
significant increase of hsTnI serum concentrations in
patients with diastolic dysfunction grade III.27
Furthermore, measurement of hsTnI in addition to
the known biomarker NT-proBNP does not produce
an increased significance to the diagnostic and prog-
nostic value. To contextualize this finding and draw
conclusions towards the conditions related to the ori-
gins of HFpEF, the characteristics of the protein itself
need to be outlined. TnI is the inhibitory subunit of the
contractile troponin complex in striated muscles.
During the systolic phase, when the intracellular (IC)
Ca concentration rises, TnI binds to the regulatory tro-
ponin C (TnC) unit. TnI inhibition gets lifted and the
muscle contraction is activated. Consequently, IC-Ca
concentrations and proteins influencing IC-Ca-balance
regulate the cardiac contraction and relaxation cycle.
Several studies have demonstrated that TnI has a dis-
crete status in the dynamics of cardiac contraction–
relaxation as it desensitizes the contractile apparatus
to activation by Ca.21,27 As a result, a sufficient diastol-
ic function is only to be achieved by adequate Ca and
TnI concentration.27
A previous study has referred to decreased TnI con-
centration in the hearts of elderly patients,27 essentially
supporting the lack of significance shown in the present
cohort. A different study argued that TnI mutations
leading to loss of function is associated with the genesis
of diastolic dysfunction.23,27 These findings, along with
other studies that confirm a higher incidence of HFpEF
in elderly patients, suggest a parallel hypothesis. The
decreased concentrations of TnI and the higher
Figure 2. Receiver-operating characteristic curves (ROC)
revealing valuable discrimination of patients with diastolic dys-
function III by hsTnT (panel A) and by hsTnI (panel B).
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incidence of HFpEF in the elderly could indicate a
possible relationship existing between the pathophysi-
ology of this syndrome and the reduced TnI
concentrations.
General research on TnI supports a case against cell
decay as a major factor causing HFpEF, as in this sce-
nario, there would have been some measurable increase
in the TnI concentrations. However, considering the
occurrence of increased TnT concentrations, the possi-
bility of the generally decreased TnI concentration in
the elderly cohort needs to be considered masking the
levels of cell decay and thereby distorting
an evaluation.
Study limitations
The validity of this study is restricted by the small size
of the collective. Furthermore, patients screened
for this study usually presented themselves with heart
failure symptoms in various stages of HFpEF and
underwent hospital treatment. Even though all echo-
cardiographic examinations were executed according
to the ESC guidelines, some level of discrepancy must
be taken into account. Accordingly, the level of the
AUCs was rather moderate, and an overinterpretation
needs to be avoided. No serial biomarker measure-
ments were performed in this study. The present results
need to be re-evaluated by larger prospective echocar-
diography studies, additionally to prove the potential
for a causal effect in between hsTnT and HFpEF.
Conclusions
HsTnT as a biomarker in the diagnosis of HFpEF
reveals significant diagnostic value as a biomarker to
classify patients with profound HFpEF, whereas hsTnI
serum concentrations did not add information for the
stages of HFpEF.
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